Boston Therapeutics — Investor Presentation (October 2012)
32 slides from Boston Therapeutics's investor presentation, Oct 10, 2012
Slide 1: Boston Therapeutics: Innovators in Complex Carbohydrate Chemistry
Boston Therapeutics Innovators in Complex Carbohydrate chemistry. OTCQB : BTHE
Slide 2: Mission
Mission: To Develop and bring to market complex carbohydrate therapeutics in diabetes
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Any statements about any possible future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements, which are subject to the saf
Slide 4: Company Overview
Company Overview Boston Therapeutics (BTHE: OTCQB) is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s initial products are: PAZAMET™, a chewable metformin tablet for the treatment of Type 2 diabetes and pre-diabetes SUGARDOWN® , a chewable
Slide 5: Complex Carbohydrate Chemistry Platform
Complex Carbohydrate Chemistry Platform Applied Carbohydrate Chemistry Pharmaceutical and OTC Consumer Product Validation in clinical trials Naturally derived raw material Generally Regarded as Safe (GRAS) Complex Carbohydrate FDA approved GRAS Chemistry OTC Consumer Product Development Pharmaceutic
Slide 6: Products
PRODUCTS OTC Consumer Product: SUGARDOWN® is a non-systemic, chewable dietary supplement designed to moderate post-meal blood glucose. It is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes which bre
Slide 7: Commercialization Strategy: Dual Paths
COMMERCIALIZATION STRATEGY: DUAL PATHS OTC DIETARY SUPPLEMENT Initial Target Markets U.S China Italy Commercially Available Validated in Clinical Study 2011 Complex Carbohydrate FDA GRAS* Material PHARMACEUTICAL PAZ320 Clinical Trial Validation in clinical trial Dartmouth-Hitchcock Medical Center Ph
Slide 8: Near-term Revenue, Long Term Growth
Near-term Revenue, Long Term Growth REVENUE From active pharmaceutical ingredient as dietary supplements Omega-3 food supplement PAZ320 Clinical Trials FDA Approval as OTC & Prescription Drugs Sales: $937M (1H 2012) Physicians, Educators MARKETING Retail, Direct Response
Slide 9: Addressable Market for SUGARDOWN, PAZAMET & PAZ320
Addressable Market for SUGARDOWN®, PAZAMET™ & PAZ320 Prevalence of Diabetes United States China Europe Prevalence of Pre-diabetes United States 2011 26 Million 92 Million 53 Million 50 Million 2011 79 Million
Slide 10: U.S. Diabetes Economic Impact
U.S. Diabetes Economic Impact Estimated diabetes costs in the United States, 2007 Total (direct and indirect) $174 billion Direct medical costs $116 billion Indirect costs (disability, work loss, premature mortality) $58 billion
Slide 11: SUGARDOWN -- OTC Dietary Supplement
SUGARDOWN® -- OTC DIETARY SUPPLEMENT Convenient Chewable Delivery Clinically Proven Safe Effective Ready for Market Mass Market Appeal Made in the U.S.A. Good Manufacturing Procedure (GMP) FOR HEALTHY, OVERWEIGHT, DIABETIC OR PRE-DIABETIC Dose Escalation Glucose Response Healthy Volunteers 170.0 150
Slide 12: How SUGARDOWN Works -- Mechanism of Action
HOW SUGARDOWN® WORKS -- MECHANISM OF ACTION WITHOUT SUGARDOWN ® Enzymes Break down Complex Sugars into Simple Sugars Complex sugars from Food More Glucose Available for Absorption (BAD) WITH SUGARDOWN ® Inhibits Carbohydrate-hydrolizing Enzymes SUGARDOWN ® Complex sugars from Food Less Glucose Avail
Slide 13: Allosteric Inhibition
Allosteric Inhibition Carbohydrate Hydrolyzing Enzyme Active site SH Known active form SH Known inactive form Allosteric binding site RESULTS Carbohydrate Hydrolyzing Enzyme Active form Substrate Allosteric inhibitor with SUGARDOWN® Allosterically inhibited form with SUGARDOWN® Inhibitor SH Active f
Slide 14: Clinical Trials: University of Sydney Phase I
CLINICAL TRIALS Research Group : University of Sydney Study : Phase I Determination of the postprandial glucose and insulin responses of white rice alone and white rice consumed with SUGARDOWN® Study design: Single center, randomized, controlled, crossover, dose-escalation study Status : Completed 2
Slide 15: Clinical Trials: Dartmouth-Hitchcock Phase II
CLINICAL TRIALS Research Group : Dartmouth-Hitchcock Medical Center Study : Phase II: Evaluate the Safety and Efficacy of PAZ320 when added to Oral Agents or Insulin regimen in Patients with Type 2 Diabetes Status : Independent Review Board (IRB) approved July 2011 Enrollment completed, June 2012. F
Slide 16: SUGARDOWN Consumer Website
SUGARDOWN® Consumer Website Simple & Effective Chew Two Tablets Before a Meal & Maintain Your Post-Meal Blood Sugar Levels. "I was diagnosed with T2 diabetes a couple years ago. I try to stay with natural alternatives to drugs, so I kind of reject taking Metformin which was prescribed to me. As a re
Slide 17: What Consumers Have to Say
WHAT CONSUMERS HAVE TO SAY... “I've been entertaining friends from France, and have been eating out more these past few days, up to 2x a day. With SUGARDOWN®, I've been getting totally normal blood sugar levels, 95 fasting, and under 130 post-meal.“ “I took 2 tablets of SUGARDOWN® before eating a bo
Slide 18: PAZAMET chewable metformin
PAZAMET™ is a new, chewable tablet formulation of the diabetes drug metformin hydrochloride that helps to control/manage blood glucose BTHE won FDA approval to file an Abbreviated New Drug Application (ANDA) for PAZAMET™ to treat diabetes PAZAMET™ is taken before meals and works in the gastrointesti
Slide 19: Glycoprotein Oxygen Carrier (GOC) Therapeutics
GLYCOPROTEIN OXYGEN CARRIER (GOC) THERAPEUTICS Safe molecule Stable shelf-life up to 5 years at room temperature No blood-type matching required No supplemental oxygen required No supply shortages Can enter narrowed capillaries better than red blood cells (RBC) Poised to compete with Hemopure®, Poly
Slide 20: Glycoprotein Oxygen Carrier (GOC) Therapeutics: Indications
GLYCOPROTEIN OXYGEN CARRIER (GOC) THERAPEUTICS Trauma Respiratory Diseases Congestive Heart Failure Multiple Organ Failure Cancer Unstable Angina Hemorrhagic Stroke Peripheral Arterial Disease More than 1 million lower limb amputations due to diabetes each year Source: World Health Organization (WHO
Slide 21: Product Pipeline
PRODUCT PIPELINE PHARMACEUTICAL PAZAMET TM PAZ320 Ipoxyn TM OxyFex TM BTI-9 CONDITION Diabetes Diabetes IV Oxygen Therapeutic (Human) IV Oxygen Therapeutic (Vet) Crohn's Disease MARKET STATUS ANDA Petition Approved 9/12; File ANDA in 2013* Phase II trial commenced 12/11 Enrollment Completed 06/12 Pr
Slide 22: Company Profile
Company Profile Boston Therapeutics, Inc. Headquarters: Manchester, New Hampshire Founded: 2009 Ticker: OTCQB: BTHE Market Cap: $8.8 Million Shares Outstanding (9/30/12): 17,348,206 52 Week Range: $.30 - $1.05 Insider Ownership 67.2% Legal Counsel: Seyfarth Shaw LLP Auditor: McGladrey LLP
Slide 23: Recent Developments: 2012/2013 Milestones
Recent Developments: 2012/2013 Milestones Received purchase orders/shipped SUGARDOWN® to Advance Pharmaceutical (APC) in Hong Kong and to distributor in Italy: April 2012. PAZ320 interim Phase ll clinical trial results indicated no safety concerns; enrollment completed: June 2012. Received FDA appro
Slide 24: Offering Terms
Offering Terms Boston Therapeutics, Inc. Offering Amount Securities Offered Stock Price Warrant Terms Shares Issued and Outstanding (9/30/12) Float (9/30/12) Public Offering $8,000,000 - $10,000,000 One share of Common Stock and one-half Warrant to Purchase and additional one-half Share of Common St
Slide 25: Use of Proceeds
Use of Proceeds Use* Launch expenses for SUGARDOWN® File ANDA for PAZAMET™ Initiate a Phase lll clinical study on PAZ320 with Metformin for diabetes* Conduct a Phase lV clinical study of SUGARDOWN® with Metformin* Conduct pre-clinical studies for IPOXYN™ for oxygen delivery in hypoxia, trauma and an
Slide 26: Intellectual Property
Intellectual Property SUGARDOWN® & PAZ320 US5527770 Extraction method for neutrally charged polysaccharide similar to SUGARDOWN® manufacturing method US5891861 Acetylated Glucosamine which recognizes monosaccharides to act as acceptor. SUGARDOWN® is the acceptor; glucose is the metabolite US5681923
Slide 27: Balance Sheet
Balance Sheet Cash and Cash Equivalents Current Assets Total Assets Accounts Payable Accrued Expenses Total Liabilities Total Shareholders’ Equity TOTAL LIABILITIES and SHAREHOLDERS EQUITY 06/30/2012 $417,510 447,737 1,316,792 335,954 133,851 767,625 549,167 $1,316,792 12/31/2011 $225,995 254,922 1,
Slide 28: Complex Carbohydrate Chemistry Platform
Complex Carbohydrate Chemistry Platform Editor of “ Carbohydrate Drug Design” and “ Galectins” , two influential volumes in the design of carbohydrate drugs and carbohydrate receptors Inventor on more than 50 patents Authored peer-reviewed articles Founded three publicly traded biotech companies Man
Slide 29: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM DAVID PLATT, Ph.D. Chairman and Chief Executive Officer Dr. Platt is a world-renown expert in carbohydrate chemistry and has founded three publicly-traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led
Slide 30: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM JOHN CORELLA Marketing Director Mr. Corella has been working in the public relations, marketing, media and technology arenas for more than 25 years, both domestically and internationally. Mr. Corella is the founder of CMME, a targeted communications company focused on pro
Slide 31: Investment Highlights
INVESTMENT HIGHLIGHTS Recently received FDA approval to file an ANDA for PAZAMET™ to treat diabetes Initiated launch of SUGARDOWN® in the U.S. at the Endocrine Annual Meeting; beginning to generate revenue Commercializing SUGARDOWN® through direct response in the U.S., and through distribution and l
Slide 32: Boston Therapeutics, Inc. Contact
BOSTON THERAPEUTICS, INC. Anthony Squeglia Investor Relations Phone : 603-935-9799 Email : [email protected] Web : www.bostonti.com Investor Relations Firm MZ GROUP Scott Powell Senior Vice President Phone : 212-301-7130 Email : [email protected] Web : www.mz-ir.com
Boston Therapeutics — Investor Presentation (October 2012) on 6ix